meRfi®-GM
Faecalibacterium prausnitzii
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
GeneBankAC: FP929045, FP929046
Faecalibacterium prausnitzii is an abundant gut commensal with potent anti-inflammatory properties mediated through cytokine modulation, tight junction fortification, and epigenetic effects, making it a potential therapeutic target for Inflammatory Bowel Disease (IBD).
It is a member of Clostridium cluster XIVa
Abundance and Taxonomy
- It is a species found in the healthy human gut microbiome, comprising around 3.52% of all gut species
- It is more closely related…
References (Sources)
- Baseline human gut microbiota profile in healthy people and standard reporting template
- Clostridium species as probiotics: potentials and challenges
- Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
- Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease
- Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease
- Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn’s Disease
- The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition